Compare Citius Pharmaceuticals Inc (CTXR) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Direxion Daily FTSE China Bull 3x Shares trades at $29.12. Which is the better fit depends on your goals.
| CTXR | YINN | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $56.62 |
52-Week Low | $0.48 | $21.45 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
YINN, a leveraged ETF tracking the FTSE China Bull 3x strategy, trades at $28.93, down 10.43% in 24 hours amid broad bearish technical signals. The fund lacks traditional financial ratios due to its structure, with a dividend of $0.21 scheduled for June 2026. Recent news highlights China's economic stimulus and AI investments, but geopolitical tensions and regulatory risks persist.
Outlook remains cautious due to leverage amplifying volatility; opportunities exist if Chinese equities rebound, but risks include US-China friction and economic slowdowns. Investors should weigh the ETF's high-risk profile against potential gains from China's tech growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
